• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Optimizing the Long-Term Therapy with Eculizumab (ECU) for Atypical Hemolytic Uremic Syndrome (aHUS).

作者信息

Santangelo Luisa, Netti Giuseppe Stefano, Mazza Sebastiano, Zito Francesca, Catalano Valeria, Martino Marida, Torres Diletta Domenica, Carbone Vincenza, Ranieri Elena, Giordano Mario

机构信息

Unit of Pediatric Nephrology, University Hospital "Policlinico Consorziale - Giovanni XXIII", Bari, Italy.

Unit of Clinical Pathology, Advanced Research Center on Kidney Aging (A.R.K.A.), Department of Medical and Surgical Sciences, University of Foggia, Viale Luigi Pinto, 71122, Foggia, Italy.

出版信息

Indian J Pediatr. 2024 Feb;91(2):205. doi: 10.1007/s12098-023-04817-0. Epub 2023 Sep 30.

DOI:10.1007/s12098-023-04817-0
PMID:37776486
Abstract
摘要

相似文献

1
Optimizing the Long-Term Therapy with Eculizumab (ECU) for Atypical Hemolytic Uremic Syndrome (aHUS).优化依库珠单抗（ECU）治疗非典型溶血性尿毒症综合征（aHUS）的长期疗法。
Indian J Pediatr. 2024 Feb;91(2):205. doi: 10.1007/s12098-023-04817-0. Epub 2023 Sep 30.
2
Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update.补体功能检测在监测非典型溶血尿毒综合征患者依库珠单抗治疗中的作用：更新。
Pediatr Nephrol. 2018 Mar;33(3):457-461. doi: 10.1007/s00467-017-3813-2. Epub 2017 Oct 18.
3
Autoimmune-type atypical hemolytic uremic syndrome treated with eculizumab as first-line therapy.以依库珠单抗作为一线治疗的自身免疫型非典型溶血性尿毒症综合征
Pediatr Int. 2015 Apr;57(2):313-7. doi: 10.1111/ped.12469.
4
Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.补体因子H杂交基因所致血浆置换抵抗性复发性非典型溶血尿毒综合征的依库珠单抗成功治疗7年：病例报告
Transplant Proc. 2018 Apr;50(3):967-970. doi: 10.1016/j.transproceed.2018.02.012.
5
Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene.依库珠单抗对一名携带CFHR1/CFH杂合基因的非典型溶血尿毒综合征患者进行的三个月间隔治疗
CEN Case Rep. 2019 May;8(2):139-143. doi: 10.1007/s13730-019-00383-7. Epub 2019 Feb 4.
6
Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.补体基因中的致病性变异与依库珠单抗停药后非典型溶血尿毒症综合征复发的风险。
Clin J Am Soc Nephrol. 2017 Jan 6;12(1):50-59. doi: 10.2215/CJN.06440616. Epub 2016 Oct 31.
7
Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.监测非典型溶血性尿毒症综合征患者依库珠单抗治疗的补体功能检测。
J Thromb Haemost. 2014 Sep;12(9):1440-8. doi: 10.1111/jth.12615. Epub 2014 Jul 16.
8
Atypical hemolytic-uremic syndrome.非典型溶血尿毒综合征
Duodecim. 2017;133(6):539-47.
9
Postpartum atypical hemolytic uremic syndrome with complement factor H mutation complicated by reversible cerebrovascular constriction syndrome successfully treated with eculizumab.产后非典型溶血性尿毒症综合征合并补体因子H突变并伴有可逆性脑血管收缩综合征，使用依库珠单抗成功治疗。
Thromb Res. 2017 Mar;151:79-81. doi: 10.1016/j.thromres.2017.01.013. Epub 2017 Feb 2.
10
Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.依库珠单抗在日本成人非典型溶血性尿毒症综合征患者中的安全性和有效性：上市后监测的中期分析
Clin Exp Nephrol. 2019 Jan;23(1):65-75. doi: 10.1007/s10157-018-1609-8. Epub 2018 Jun 29.

本文引用的文献

1
Pharmacological Management of Atypical Hemolytic Uremic Syndrome in Pediatric Patients: Current and Future.儿科患者非典型溶血性尿毒综合征的药物治疗：现状与未来。
Paediatr Drugs. 2023 Mar;25(2):193-202. doi: 10.1007/s40272-022-00555-6. Epub 2023 Jan 13.
2
Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way.依库珠单抗治疗非典型溶血性尿毒症综合征（aHUS）的最佳疗程——一个有待以科学方式解决的问题。
Pediatr Nephrol. 2019 May;34(5):943-949. doi: 10.1007/s00467-019-4192-7. Epub 2019 Jan 28.
3
Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.
补体基因中的致病性变异与依库珠单抗停药后非典型溶血尿毒症综合征复发的风险。
Clin J Am Soc Nephrol. 2017 Jan 6;12(1):50-59. doi: 10.2215/CJN.06440616. Epub 2016 Oct 31.
4
An international consensus approach to the management of atypical hemolytic uremic syndrome in children.儿童非典型溶血性尿毒症综合征管理的国际共识方法。
Pediatr Nephrol. 2016 Jan;31(1):15-39. doi: 10.1007/s00467-015-3076-8. Epub 2015 Apr 11.